3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Salivary Gland Neoplasms
3
Endometrial Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
fludarabine
5
Cyclophosphamide
5
aldesleukin
4
fludarabine phosphate
2
entinostat
2
Trastuzumab
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tipifarnib
1
bintrafusp alfa protein, human
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Indinavir
1
Immunotherapy
1
Fluorodeoxyglucose F18
1
Fentanyl
1
FAPI-46
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaginal Neoplasms
×
trastuzumab deruxtecan
×
Head & Neck
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled